[Colony stimulating factors in blood formation].
The aim of this article is to review the present state of knowledge of the clinical effects of the colony-stimulating factors. Clinical experience and publications on this subject are used for this purpose. Colony-stimulating factors are being successfully used in various diseases and clinical situations, particularly in the area of hematology/oncology. However, numerous questions still remain. There are many new untested areas in which filgrastim could be employed. New indications and open questions require suitable new studies.
Goebel
M
M
Hoffmann-La Roche Ltd., Basel, Schweiz.
D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000628:therapy; D003131:Combined Modality Therapy; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D009503:Neutropenia / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D010166:Palliative Care; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor